Neurogene Inc.: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Balyasny Asset Management L.P. amended its Schedule 13G stake filing for Neurogene Inc., disclosing the change to the SEC under accession number 0001172661-26-005052. The filing updates the hedge fund's previously reported beneficial ownership position in the clinical-stage gene therapy developer. Schedule 13G amendments are typically triggered when a passive investor's stake crosses or moves past the 5% threshold or when holdings change materially. The exact revised share count and ownership percentage were not specified in the headline disclosure. Investors will watch for the full filing details to gauge whether Balyasny increased or trimmed its position in Neurogene.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Balyasny Asset Management L.P., Neurogene Inc.